DxVx

Dx&Vx(www.dxvx.com) is a total healthcare solution provider in South Korea. Dx&Vx was established in 2001 and started genomic testing services for the first time in the Korean market in 2007 and listed on the Korean stock exchange KOSDAQ in 2015. The business scopes we have are Microbiome drugs, Digital DX services and IVD kits, New drugs/vaccines, and genomic analysis services, Since 2007, we have provided NIPT(Non-invasive prenatal testing) services for more than 15 years with over 27,000 accumulated testing cases. Not only the prenatal services but also postnatal, and even PGT, we penetrated the domestic market as a top-tier player in the market. Our genomic analysis testing service, GenomeCheck can provide reliable test results with 99% of test accuracy, and a 1.3% of test failure rate.